In the Asthma Drug Market, Generic Erosion Will Reduce Sales of Merck/Kyorin’s Singulair by More Than $2.8 Billion Between

  In the Asthma Drug Market, Generic Erosion Will Reduce Sales of
  Merck/Kyorin’s Singulair by More Than $2.8 Billion Between 2011 and 2021

The Overall Market for Asthma Therapies Will Be Relatively Flat Over the Next
    Decade, With Sales Close to $15 Billion in 2011 and 2021, According to
                       Findings from Decision Resources

Business Wire

BURLINGTON, Mass. -- December 19, 2012

Decision Resources, one of the world’s leading research and advisory firms for
pharmaceutical and healthcare issues, finds that Merck/Kyorin’s Singulair is a
dominant player among maintenance therapies in the asthma market, attaining
sales of nearly $3.2 billion and the second-highest patient share in the major
markets in 2011. However, generic versions of Singulair launched in the United
States in 2012, and Decision Resources expects further sales losses as
generics enter the European markets in 2013 and the Japanese market in 2016.
As a result, sales of Singulair will shrink to $360 million in 2021 in the
United States, France, Germany, Italy, Spain, the United Kingdom, and Japan.

The upcoming Pharmacor advisory service entitled Asthma, which will be
published soon, also finds that the overall market for asthma therapies will
be relatively flat over the next decade, with sales increasing slightly by
approximately $200 million from 2011 to 2021. Pricing pressure due to generic
and/or branded-generic price erosion and increased product competition will
constrain the market, but the uptake of high-priced once-daily fixed-dose
combinations and novel anticytokine agents will grow sales.

“The asthma marketplace is saturated with effective, well-established
treatments and increasing generic competition in the United States and Europe
and heightened cost-consciousness in the major markets will drive increased
competitiveness in this space,” said Decision Resources Analyst Colleen
Albacker, Ph.D. “Evaluation of the late-stage pipeline for asthma indicates
that commercial success will hinge on clearly messaging the advantages of
incremental gains in safety, efficacy, convenience, and pricing to
differentiate emerging players from competitors as none appear to offer
significant strides over marketed therapies.”

The findings also reveal that, starting from 2015, three novel anticytokine
agents are expected to launch for the treatment of severe,
corticosteroid-refractory asthma and infuse a competitive dynamic to this
segment of the market that is currently underserved by the availability of
only one pharmacological option, Genentech/Novartis’s Xolair. These novel
biologics will begin to fulfill an important unmet need for severe, refractory
patients, and their launch will signify a move toward personalized medicine
for the treatment of asthma.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market
research publications, advisory services and consulting designed to help
clients shape strategy, allocate resources and master their chosen markets.
Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources Group at
www.DecisionResourcesGroup.com.

    All company, brand, or product names contained in this document may be
       trademarks or registered trademarks of their respective holders.

Contact:

Decision Resources
Christopher Comfort, 781-993-2597
ccomfort@dresources.com
 
Press spacebar to pause and continue. Press esc to stop.